You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
- 2. A bibliometric analysis of liver cancer bone metastases: advances in mechanisms of occurrence and treatment options
- 3. Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
- 4. BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient
- 5. Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer
- 6. Radiopharma's new wave: Nuclidium and Actithera raise the stakes
- 7. ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
- 8. ESCO2 inhibition induces cell cycle arrest and apoptosis in breast cancer via the P53-CDK1 axis and the BAX/Bcl2/caspase signaling cascade
- 9. Baseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
- 10. Ultrasound-based radiomics combined with B3GALT4 level to predict sentinel lymph node metastasis in primary breast cancer
Last updated at 10:33 GMT
Hot News Makers
Health/Pharma Companies
-
30397.46
-
23642.47
-
22997.92
-
7603.44
-
7347.36
-
3378.74
-
3209.69
-
2724.79
-
2198.69
-
2050.56
Drugs, Treatments, Trials
-
28939.26
-
17524.55
-
4760.43
-
2391.64
-
1503.29
-
1009.25
-
984.92
-
921.37
-
745.94
-
612.03
Last updated at 10:10 GMT
